Patients with hypertension coupled with metabolic syndrome (MetS) are among the high risk population in cardiovascular and cerebrovascular diseases. To reduce the prevalence of cardiovascular and cerebrovascular diseases, it is essential to appropriately control blood pressure together with other cardiovascular risk factors. OBJECTIVE: The current study was designed to investigate the therapeutic effects on blood pressure, blood pressure variability and other cardiovascular risk factors by giving Yiqi Huaju Formula, a compound traditional Chinese herbal medicine, in addition to routine treatment to hypertensive patients coupled with MetS.
Introduction
Hypertension can cause severe damage to the heart, brain and kidneys. The prognosis is worse in patients who suffer from complications of metabolic syndrome (MetS) and have a variety of other cardio-cerebrovascular risk factors. In MetS patients coupled with hypertension, the relative risk of cardiovascular disease doubles [1] ; hypertensive subjects with three or more components of MetS exhibit a three-fold higher risk for cardiac events, 2.59 for cerebrovascular events, and 2.26 for total cardiovascular events compared with those without MetS [2] . In an epidemiological study that enrolled a total of 1 742 hypertensive patients without cardiovascular diseases, who were followed up for 10.5 years (mean 4.1 years), event rates in the groups with one to five characteristics of MetS were 1.54, 1.96, 2.97, 3.35, and 5.27 per 100 patient yearly, respectively (P < 0.01). Patients with MetS had almost double cardiovascular event rates compared with those without (3.23 vs 1.76 per 100 patientyears, P < 0.01) [3] . Therefore, MetS patients require stricter control of blood pressure, which is essential to diminish other cardiovascular disease risk factors. For example, the ideal blood pressure level of a hypertensive patient with complications of diabetes mellitus or albuminuria should be lower than 130/80 mmHg. However, there is general poor clinical management of patients with MetS coupled with hypertension. The reason could be twofold. First, it is not feasible for hypertensive patients, especially ones with abdominal obesity, to efficiently control their blood pressure by means of conventional drugs alone [4] . Second, although antihypertensive drugs exert strong pharmacological effects in controlling blood pressure, they do little to improve other cardiovascular risk factors. Previous research under the guidance of traditional Chinese medicine theory has demonstrated that application of Yiqi Huaju Formula on MetS patients can effectively reduce a variety of cardiovascular disease risk factors [5, 6] . The aim of the current study is to develop a treatment protocol that contains both Yiqi Huaju Formula and conventional antihypertensive drugs for those uncontrolled hypertensive patients with MetS. This trial was conducted to determine if such a protocol could be useful in controlling blood pressure as well as other cardiovascular risk factors.
Materials and methods
This prospective, randomized, double-blind trial was conducted in accordance with the Declaration of Helsinki. The sample size was calculated by the formula of n=[p1*(100-p1)+p2*(100-p2)]*f(α,β)/(p2-p1) 2 (p1: the effective ratio of standard treatment, was 60%-70% [7] ; p2: the predicted effective ratio of Yiqi Huaju Formula preceding the standard treatment, was 90.0% [6] ; α: error of the first kind, means 0.05; β: error of the second kind, was 0.2; f(α, β) as checked by the statistical table was 7.9). The sample size was 44 according to the result of the formula. The study protocol was reviewed and approved by the Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine (No. 2011-9), and was registered in Chinese Clinical Trail Registry (Trial registration identifier: ChiCTR-TRC-11001633). Written informed consent was obtained from each individual prior to participation in the study.
Inclusion criteria
(1) Age: 18-65 years old. (2) MetS was diagnosed with two or more of the following criteria according to the guidelines issued by the Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults in 2007 [8] . (3) Hypertension was diagnosed in accordance with the guidelines of the Joint National Committee (JNC7) [9] by a 24-hour ambulatory blood pressure monitor (24-h ABPM): hypertensive individuals have an average blood pressure of > 135/85 mmHg when awake and > 120/75 mmHg during sleep; or systolic blood pressure (SBP) ≥ 140 mmHg, and/or diastolic blood pressure (DBP) ≥ 90 mmHg, which was based on the average of 2 or more properly measured, seated BP readings on each of 2 or more office visits. (4) All included patients had signed written informed consent.
Exclusion criteria
(1) Hypertensive crisis; (2) SBP > 180 mmHg, and/or DBP > 110 mmHg; (3) secondary hypertension; (4) secondary obesity, or obesity due to drugs; (5) concurrent other conditions, such as serious heart disease, kidney disease, liver disease, or tumors; pregnant or breastfeeding women; patients with mental disorders.
Subjects
This trial was conducted at the Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine from October 1, 2011 to October 1, 2012. A total of 43 patients who met the selection criteria were recruited. Random number list was generated by Excel 2007 software (Microsoft Co., 2007, USA) before the study. Pieces of paper with a random number generated from the list were placed into envelopes. Each participant received an envelope upon recruitment into the study. The participants assigned odd numbers were allocated to the Chinese herbal formula (CHF) group and the participants with even numbers were allocated to the control group. A researcher who did not know the details of the project was in charge of drug distribution and recycling. All of the participants were blinded to the treatment of CHF or Journal of Integrative Medicine placebo (1 bag per dose, twice a day) for 12 weeks.
Basic interventions
The participants of both groups were educated on diet control (reducing the grain food to 100 to 150 g/d and decreasing intake of salt, sugar and fat) and proper exercise as a basic treatment [10] . Patients continued their antihypertensive and/or antihyperglycemic treatments used prior to the study. The anti-hypertension drugs included calcium channel blockers (CCB) such as amlodipine 5 mg per day, angiotensin receptor blockers (ARB) such as valsartan 80 mg per day, respectively or additionally.
CHF group
The Yiqi Huaju Formula was taken orally by patients in the CHF group. The Yiqi Huaju Formula was produced in the form of granules by the Department of Pharmacy at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine (batch number: 110501). It was composed of Huangqi (Astragali Mongholici) 12 g, Huanglian (Rhizoma Coptidis) 3 g, Puhuang (Pollen Typhae) 7.5 g, Zexie (Rhizoma Alismatis) 5 g, and Yinchen (Artemisiae Capillaries) 7.5 g. Each bag contained 17.5 g crude herbs, which was dissolved in boiling water and drunk while still warm. Patients in the CHF group took one bag of Yiqi Huaju granule twice a day for 12 weeks.
Control group
Placebo was taken by patients in the control groups. Placebo was made by using Yiqi Huaju Formula at a 1/20 dose as a molding agent and a flavoring agent (batch number: 110601). The appearance and taste of the placebo granules were made up to be similar to the Yiqi Huaju granules. Instruction for usage was the same as Yiqi Huaju Formula.
Measured indices 2.4.1 Anthropometric index
Before and after treatment, anthropometric indices such as body height (BH), body weight (BW), waist circumference (WC) and hip circumference (HC) were measured. Body mass index [(BMI) = BW (kg)/BH (m) 2 ] and waist-to-hip ratio [(WHR) = WC (cm)/HC (cm)] were calculated.
Blood sample collection and analyses
After 12 h of fasting, venous blood was collected from all participants at 8:00 AM. Then 75 g oral glucose was taken by all the participants for glucose tolerance test. Two hours later, venous blood was collected for test of 2-hour postprandial plasma glucose (2-hPPG). Fasting plasma glucose (FPG), 2-hPPG, total cholesterol (TC) and triacylglycerol (TAG) were measured by enzymatic method (kits produced by Shanghai Jin-Yuan Medical Equipment Co., Ltd, China). High-density lipoprotein cholesterol (HDL-C) was measured by enzymatic method (kits produced by Sekisui Medical Co., Ltd, Japan). Low-density lipoprotein cholesterol (LDL-C) was measured by clearance method (kits produced by Sekisui Medical Co., Ltd, Japan). All the parameters stated above were analyzed by the Hitachi 7600 automatic biochemical analyzer (Hitachi Co., Japan). Glycosylated hemoglobin (HbA1c) was measured by high-performance liquid chromatography (kits produced by Sysmex Corporation, Japan). Fasting plasma insulin (FPI) was measured by chemilluminescence method (Siemens Company, CENTAUR XP automatic chemical luminescence immunity analyzer, German). Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated by the formula HOMA-IR= FPG (mmol/L) × FPI (mU/L)/22.5.
Ambulatory blood pressure monitoring
Blood pressure was monitored using SunTech Medical Oscar 2 (Suntech, USA). There were no required limitations to activities during monitoring. The cuff was belted onto the non-dominant arm. The portable monitors were programmed to obtain 24-hour ambulatory blood pressure readings at 30-minute intervals during daytime and 45-minute intervals during nighttime, beginning from 8:00 AM. The report was edited by blood pressure data analysis software. Standard effective blood pressure reading range was SBP: 70-260 mmHg, DBP: 40-150 mmHg; pulse pressure: 20-120 mmHg; numbers outside of that range were considered invalid.
Daytime was defined as the time from 7:00 AM to 9:59 PM and nighttime was from 10:00 PM to 6:59 AM. Mean arterial blood pressure (MBP) implied the average of the blood pressure data in the relevant time period. Blood pressure variability (BPV) was the standard deviation of mean blood pressure in the relevant time period. Blood pressure load was the percentage of the sum counting of SBP ≥ 140 mmHg and DBP ≥ 90mmHg in the total count within 24 h. According to the above definition, we obtained blood pressure data such as SBP, DBP, MBP, SBP variability (SBPv), DBP variability (DBPv), MBP variability (MBPv), SBP load (SBPp), and DBP load (DBPp) over 24 h, during both daytime (d) and nighttime (n).
Security index
Before and after treatment, routine blood and urine tests, liver and renal function tests, electrolytes, and electrocardiograms were examined and analyzed.
Statistical analyses
The data were analyzed using SPSS 16.0 software (SPSS, Chicago, IL, USA; version 16). Data were described as mean ± standard deviation. Proportions were used to express dichotomous variables. Group t test was used to compare the difference between two groups. The paired t test was used to compare data before and after treatment. Correlation analyses (Pearson) and Chi-square test were performed according to different purposes, respectively. A P-value of less than 0.05 was considered as significant.
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Results

Baseline characteristics
There were 22 patients enrolled in the CHF group (14 men and 8 women), and the average age was (48.73 ± 9.44) years old. Sixteen patients had grade 1 hypertension and six patients had grade 2 hypertension; five patients were diagnosed with type 2 diabetes mellitus (T2DM). The control group had 21 cases (14 men and 7 women) with an average age of (48.90 ± 8.92) years old. Thirteen patients had grade 1 hypertension and eight patients had grade 2 hypertension; six patients were diagnosed with T2DM. The baseline characteristics and the ratio of antihyperglycemia, anti-hypertension and lipid-regulating treatment were comparable and statistically insignificant between the CHF group and the control group ( Table 1) . The flow chart of this trial was shown in Figure 1 .
Changes in anthropometric indices before and after treatment
Prior to the treatment, no difference in anthropometric index was observed between the two groups. After the treatment, BW, BMI, WC, and WHR in the CHF group were significantly decreased (P<0.01), while those in the control group were unchanged. There were significant differences in the levels of WC and WHR (P<0.05) between the CHF group and the control group after treatment (Table 2 ).
Changes in FPG, 2-hPPG, HbA1c, FPI, HOMA-IR, and blood lipid profile
There were no differences between the two groups in the levels of FPG, 2-hPPG, HbA1c, FPI, HOMA-IR, TC, TAG, HDL-C, and LDL-C before treatment. After the treatment, the levels of FPG, 2-hPPG, FPI and HOMA-IR in the CHF group were significantly decreased (P<0.01 or P<0.05), but the same measures in the control group did not exhibit significant changes. The levels of 2-hPPG, FPI, and HOMA-IR in the CHF group were lower than those in the control group (P<0.05). The blood lipid profile in both groups displayed no obvious changes after treatment. There was no statistically significant difference between the two groups ( Table 3) .
Comparison of 24-h ABPM
Prior to interventions, there was no statistically significant difference in the blood pressure parameters measured by 24-h ABPM between the CHF group and the control group.
Changes in blood pressure at different intervals before and after treatment
In the control group, there was no significant difference in blood pressure at different intervals including 24-hour, day and night compared before and after treatment. In the CHF group, however, the levels of 24-hSBP, 24-hDBP, 24-hMBP, dSBP, dDBP, dMBP, and nSBP of the patients significantly decreased (P<0.01 or P<0.05) after the treatment. There were significant decreases (P<0.01 or P<0.05) in 24-hour diastolic blood pressure; 24-hMBP: 24-hour mean arterial blood pressure; dSBP: day-time systolic blood pressure; dDBP: day-time diastolic blood pressure; dMBP: day-time mean arterial blood pressure; nSBP: night-time systolic blood pressure; nDBP: night-time diastolic blood pressure; nMBP: night time mean arterial blood pressure. 24 -hour diastolic blood pressure variability; 24-hMBPv: 24-hour mean arterial blood pressure variability; dSBPv: day-time systolic blood pressure variability; dDBPv: day-time diastolic blood pressure variability; dMBPv: day-time mean arterial blood pressure variability; nSBPv: night-time systolic blood pressure variability; nDBPv: night-time diastolic blood pressure variability; nMBPv: night-time mean arterial blood pressure variability. the indices of 24-hSBP, 24-hDBP, 24-hMBP, dSBP, dDBP, and dMBP in the CHF group compared with the control group (Table 4) .
Changes in BPV at different intervals before and after treatment
In the control group, there was no difference in BPV at different intervals before and after treatment. In the CHF group, there were significant decreases (P<0.01 or P<0.05) in the levels of 24-hSBPv, 24-hDBPv, 24-hMBPv, dSBPv, dDBPv, dMBPv, and nDBPv after the treatment. There were significant decreases (P<0.01 or P<0.05) in the levels of 24-hSBPv, 24-hDBPv, 24-hMBPv, dSBPv, dDBPv, dMBPv, nDBPv, and nMBPv in the CHF group compared with the control group (Table 5) .
Changes in pressure load at different intervals before and after treatment
In the control group, there was no difference in pressure load at different intervals before and after treatment. In the CHF group, there were significant decreases (P<0.01 or P<0.05) in the levels of 24-hSBPp, 24-hDBPp, dSBPp, dDBPp, and nSBPp after the treatment. Significant decreases (P<0.01 or P<0.05) in the levels of 24-hSBPp, 24-hDBPp, dSBPp, dDBPp, and nDBPp were observed in the CHF group compared with the control group (Table 6 ). 
Correlation between HOMA-IR and 24-h ABPM in patients
As shown in Table 7 , there was high correlation (P<0.01) between the HOMA-IR in MetS patients and the levels of 24-hSBP, 24-hDBP, 24-hMBP, 24-hSBPp, 24-hDBPp, dSBP, dDBP, dMBP, dSBPp, dDBPp, nSBP, nDBP, nMBP, nSBPp and nDBPp. The correlation indicates that insulin resistance was possibly associated with blood pressure amplitude and volatility (Table 7) .
Safety evaluations
Two patients in the CHF group exhibited skin allergy which was resolved without treatment, and did not cause them to drop out of the study. No other adverse reaction was observed in the remaining samples. There were no abnormal findings in the routine checkup of blood and urine tests, liver and renal function tests, electrolytes, or electrocardiograms after treatment.
Discussion
Hypertensive patients are a high-risk population for development of MetS. A large observational study has shown that the prevalence of MetS in hypertensive patients over the age of 35 could be as high as 33.9% in the Han ethnic group, and 37.6% in the Mongolian ethnic group [11] .
Conversely, MetS patients are a high-risk population for development of hypertension. In a study conducted by Hong Kong Cardiovascular Risk Factor Prevalence Survey, the prevalence of hypertension was much higher in the patients with MetS than those without MetS. Moreover, this prevalence increased when the number of MetS components increased [12] . This relationship also applied to the effect of MetS on cardiovascular risk and mortality caused by hypertension. Hazard ratios (95% CI) for cardiovascular mortality increased from 1.83 (1.21-2.77) in the presence of one MetS component to 5.52 (3.48-8.75 ) in the presence of five components [13] . Given the above, it is a worthwhile public health goal to prevent and treat MetS to reduce the prevalence of cardiovascular diseases.
Controlling blood pressure well is often a difficult clinical task. The 43 patients enrolled in the current study seldom had well-controlled blood pressure, even though all but three of the patients were under conventional antihypertensive treatment. In the USA, only 36.8% of patients have blood pressure that is under control [14] . One epidemiological study in a Tianjin community of 28 518 subjects showed that the prevalence of hypertension was 27.52% and blood pressure control rate was only 26.77% [15] . Controlling blood pressure in MetS patients with hypertension is even more difficult due to the extra cardiovascular risks. The
Journal of Integrative Medicine www.jcimjournal.com/jim current conventional therapies for hypertension, hyperglycemia, and hyperlipidemia are often limited to targeting isolated physiological systems, and lack comprehensive treatment methods that effectively address a person's whole health. These therapies come with undesirable side effects for the patients, and their poor clinical efficacy results in wasted medical resources as a whole. Traditional Chinese medicine, due to its multiple targeting effects, could be one solution to this problem.
The etiology and pathogenesis of insulin resistance is interpreted in traditional Chinese medicine theory as "poor transformation due to spleen deficiency" by Prof. Wen-jian Wang [16] , a research expert on integrated traditional Chinese and Western medicine for regulating MetS. Macro-nutrients such as carbohydrates and fat become the primary causes of dyslipidemia, hyperglycemia, and visceral fatty infiltration if they are not properly digested and transformed into Jingqi that restores the body. In the context of traditional Chinese medicine, the imbalance from chronic poor transformation can cause pathogenic heat, turbid dampness and blood stasis, which are the pathogenic causes of hypertension and other cardiovascular diseases. Following this theory, Prof. Wang created the Yiqi Huaju Formula for the treatment of MetS. Previous studies have shown that some of the effective ingredients in this formula, such as Astragalus polysaccharide, Pollen typhae total flavone and berberine can increase insulin sensitivity and impact multiple molecular targets through modulating insulin resistance [17] [18] [19] . The research results showed that Yiqi Huaju Formula can increase insulin sensitivity, improve anthropometric index as well as glycometabolism and lipid metabolism, reduce visceral fat, inhibit inflammatory factors and improve fibrinolytic functions [5, 6] . Traditional Chinese medicine clinicians strive to treat the causes of disease rather than the symptoms. In terms of MetS patients with hypertension, the causes are spleen deficiency-associated pathogenic heat, turbid dampness, and blood stasis, and the symptoms are the dysfunction of vascular regulation and hypertension. The aim of this study is to observe the effects of Yiqi Huaju Formula combined with routine chemical drug therapy in controlling the causes.
The results showed that the levels of SBP, DBP and MBP over 24 h and during daytime hours in the CHF group were significantly decreased after 12 weeks of treatment. The level of SBP at nighttime in the CHF group was decreased; however, the levels of DBP and MBP at nighttime in the CHF group were not improved. In contrast, the levels of blood pressure at different intervals in the control group showed no significant differences. After treatment, the levels of SBP, DBP, and MBP of 24 h and at daytime in the CHF group were lower than those in the control group (P<0.01). These results indicate that Yiqi Huaju Formula along with antihypertensive treatment can reduce blood pressure amplitude further in MetS patients with hypertension, compared with the placebo. The antihypertensive effect during daytime was more obvious than during nighttime. This could be because the blood pressure elevates more during the daytime than at night, and thus the potential daytime changes are greater.
ABPM is able to reflect a person's overall blood pressure picture via multiple recordings, and also can be used to measure BPV to evaluate blood pressure fluctuations and calculate blood pressure load to reflect the risks of high blood pressure. The damage to target organs caused by hypertension depends not only on the range of the high blood pressure, but also on BPV, which can independently predict related target organ damage and risk of cardiovascular diseases [20, 21] . The level of BPV is positively associated with myocardial infarction and cardiovascular end event rate [22] . In addition, it has been reported that BPV of MetS patients tends to elevate easily due to complications from many other cardiovascular risk factors such as central obesity, hyperglycemia, and dyslipidemia [23] . At present, researchers mainly focus on reducing blood pressure amplitude instead of controlling BPV. There are some inconsistent reports on the effects of conventional drugs on BPV. Research conducted by ASCOT-BPLA suggested that CCBs can reduce SBPv, which resulted in a 26% greater reduction in BPV as compared to treatment with beta-blockers [24] ; 13% as compared to treatment with ACEIs; and 11% as compared to treatment with diuretics (P<0.01) [24] [25] [26] . But other studies suggested that CCBs, beta blockers and ACEI do not reduce BPV [27, 28] . The discrepancies in above results indicate that there is no reliably effective treatment for the control of BPV so far. This phenomenon existed in the current study as well. Most of the patients enrolled in the study have been using CCB or/and ARB as a conventional treatment. However, their BPV were still elevated prior to this study. The results of our study showed the levels of 24-hSBPv, 24-hDBPv and 24-h MBPv in the CHF group decreased significantly (P<0.01) and were much lower than those in the control group (P<0.01). Furthermore, the level of nDBPv in the CHF group also decreased and was lower than that in the control group (P<0.05). In contrast, there was no difference in BPV in the control group between before and after treatment. Therefore, regardless of the influence of CCB treatment on BPV, the level of BPV in the CHF group decreased after the additional use of Yiqi Huaju Formula, which indicated that Yiqi Huaju treatment may be better than antihypertensive drugs alone in the treatment of MetS patients with hypertension.
Blood pressure load can reflect frequency of blood pressure above normal threshold in hypertensive patients. In adults, higher blood pressure load has been shown to be associated with adverse cardiovascular risk profile independent of Journal of Integrative Medicine the mean blood pressure [29] . It has also been shown that increased blood pressure load is potentially a modifiable risk factor that is independently associated with the development of subclinical cardiac and renal damage [30] . In our study, there was no difference in blood pressure load at different intervals in the control group before and after treatment. However, the levels of 24-hSBPp, 24-hDBPp, dSBPp, dDBPp, and nSBPp in the CHF group decreased after the treatment (P<0.01 or P<0.05) and were much lower than those in the control group (P<0.01 or P<0.05). In particular, the level of nSBPp in the CHF group decreased more significantly (P<0.05). These results showed that the additional use of Yiqi Huaju Formula can reduce the frequency of blood pressure above normal threshold in MetS patients with hypertension, which may be important and helpful in protecting the target organs.
MetS is a clinical syndrome with a variety of cardiovascular risk factors. Controlling blood pressure is only one of the measures to reduce cardiovascular risks in MetS. The ideal intervention should be comprehensive with goals to reduce insulin resistance, central obesity and metabolic risks. Yiqi Huaju Formula has shown just such effects in previous studies. The current study confirmed that the levels of FPG, 2-hPPG, FPI, and HOMA-IR decreased with the CHF treatment (P<0.01 or P<0.05); these values in the treatment group were also lower than those of the control group (P<0.05).
BPV depends on the changes in sympathetic nervous system activity, and to some degree, on circulatory changes mechanically induced by ventilation. There are speculations that humoral vasoactive substances, changes in vascular smooth muscle reactivity, and other unknown influences are involved [31] . Besides the common factors causing hypertension, insulin resistance is one of the most important elements in MetS patients. Insulin resistance can directly increase sympathetic nervous system activity, promote renal tubular re-absorption of sodium, and increase cardiac output and peripheral vascular resistance. Moreover, it can also affect autonomic nervous system function, stimulate the secretion of norepinephrine and angiotensin Ⅱ , indirectly stimulate the sympathetic nervous system and increase the stress response of blood vessels, leading to hypertension and the increase in BPV [32] [33] [34] [35] [36] . Our study showed that hypertension is positively associated with insulin resistance in MetS patients by correlation analysis. These results suggest that the improvement of blood pressure parameters can result from the improvement of insulin sensitivity by the intervention of Yiqi Huaju treatment. The detailed mechanisms require further investigation.
Conclusions
This study examined the integrative treatment with conventional drug therapy and Chinese herbal formula of Yiqi Huaju in MetS patients with hypertension. Compared with antihypertensive drugs alone, the integrative treatment exhibited better results in reducing blood pressure amplitude, BPV and blood pressure load. At the same time, it effectively decreased the risks of vascular diseases such as central obesity and insulin resistance, and reduced the level of plasma glucose. This protocol exerts multiple actions on various MetS components, and may therefore be an effective and efficient tool in the management of hypertension coupled with MetS. 
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